title: [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
abstract: Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (EBV-PTLD) is a potentially life-threatening complication after hematopoietic stem cell transplantation or solid organ transplantation. In the last decade, the survival of patients with EBV-PTLD has been significantly improved by immunotherapeutic interventions among high-risk patients. The immunotherapeutic interventions for EBV-PTLD include reduction in immunosuppression, CD20 monoclonal antibodies (rituximab) as monotherapy or in combination with chemotherapy, and adoptive immunotherapy with EBV-specific T cells. This paper reviews the latest update on the high-risk factors, clinical manifestations and immunotherapy of EBV-PTLD.
authors.affiliation: Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. haoqingfei@hotmail.com.
authors.forename: Qing-Fei
authors.initials: QF
authors.lastname: Hao
authors.forename: Guang-Yao
authors.initials: GY
authors.lastname: Sheng
authors.forename: Zuo
authors.initials: Z
authors.lastname: Luan
mesh_terms: D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000628:therapy*; D011183:Postoperative Complications / Q000209:etiology / Q000628:therapy*; D012307:Risk Factors